Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 681

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer: A Prospective, Randomized, Open-label, Multicenter Phase 2/3 Trial

Open access
Jang, Jin-Young, Han, Youngmin, Lee, Hongeun, Kim, Sun-Whe, Kwon, Wooil, Lee, Kyung-Hun, Oh, Do-Youn, Chie, Eui Kyu, Lee, Jeong Min, Heo, Jin Seok, Park, Joon Oh, Lim, Do Hoon, Kim, Seong Hyun, Park, Sang Jae, Lee, Woo Jin, Koh, Young Hwan, Park, Joon Seong, Yoon, Dong Sup, Lee, Ik Jae, Choi, Seong Ho·2018·Annals of Surgery

Abstract

Objective: This study was performed to determine whether neoadjuvant treatment increases survival in patients with BRPC. Summary Background Data: Despite many promising retrospective data on the effect of neoadjuvant treatment for borderline resectable pancreatic cancer (BRPC), no high-level evidence exists to support the role of such treatment. Methods: This phase 2/3 multicenter randomized controlled trial was designed to enroll 110 patients with BRPC who were randomly assigned to gemcitabine-based neoadjuvant chemoradiation treatment (54 Gray external beam radiation) followed by surgery or upfront surgery followed by chemoradiation treatment from four large-volume centers in Korea. The primary endpoint was the 2-year survival rate (2-YSR). Interim analysis was planned at the time of 50% case enrollment. Results: After excluding the patients who withdrew consent (n = 8) from the 58 enrolled patients, 27 patients were allocated to neoadjuvant treatment and 23 to upfront surgery groups. The overall 2-YSR was 34.0% with a median survival of 16 months. In the intention-to-treat analysis, the 2-YSR and median survival were significantly better in the neoadjuvant chemoradiation than the upfront surgery group [40.7%, 21 months vs 26.1%, 12 months, hazard ratio 1.495 (95% confidence interval 0.66–3.36),P= 0.028]. R0 resection rate was also significantly higher in the neoadjuvant chemoradiation group than upfront surgery (n = 14, 51.8% vs n = 6, 26.1%,P= 0.004). The safety monitoring committee decided on early termination of the study on the basis of the statistical significance of neoadjuvant treatment efficacy. Conclusion: This is the first prospective randomized controlled trial on the oncological benefits of neoadjuvant treatment in BRPC. Compared to upfront surgery, neoadjuvant chemoradiation provides oncological benefits in patients with BRPC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/sla.0000000000002705

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 17 references

Cited by

See all 681

Metadata

Authors
Jang, J.-Y., Han, Y., Lee, H., Kim, S.-W., Kwon, W., Lee, K.-H., Oh, D.-Y., Chie, E. K., Lee, J. M., Heo, J. S., Park, J. O., Lim, D. H., Kim, S. H., Park, S. J., Lee, W. J., Koh, Y. H., Park, J. S., Yoon, D. S., Lee, I. J., & Choi, S. H.
Venue
Annals of Surgery
Published
2018-08
Volume
268
Issue
2
Pages
215-222
ISSN
  • 0003-4932 (ISSN-L)
  • 1528-1140
OpenAlex
W2912196744
Cited by
681
References
17
FWCI
23.84
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer: A Prospective, Randomized, Open-label, Multicenter Phase 2/3 Trial. https://app.cochat.ai/papers/10.1097/sla.0000000000002705
The paper
Jang, J.-Y., Han, Y., Lee, H., Kim, S.-W., Kwon, W., Lee, K.-H., Oh, D.-Y., Chie, E. K., Lee, J. M., Heo, J. S., Park, J. O., Lim, D. H., Kim, S. H., Park, S. J., Lee, W. J., Koh, Y. H., Park, J. S., Yoon, D. S., Lee, I. J., & Choi, S. H. (2018). Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer: A Prospective, Randomized, Open-label, Multicenter Phase 2/3 Trial. Annals of Surgery. https://doi.org/10.1097/sla.0000000000002705

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.